Paraguay
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.75 (0.13 - 20.61) | 2015 | Modelled | WHO |
| 2.99 (2.44 - 3.54) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3.27 (2.67 - 3.89) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.31 (2.73 - 3.96) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.41 (2.81 - 4.07) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.48 (2.83 - 4.14) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.51 (2.85 - 4.17) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.6 (2.92 - 4.28) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.7 (3 - 4.43) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.79 (3.06 - 4.51) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.81 (3.07 - 4.56) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.81 (3.10 - 4.51) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.83 (3.14 - 4.52) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.87 (3.17 - 4.56) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.89 (3.18 - 4.62) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.9 (3.16 - 4.66) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.92 (3.19 - 4.69) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.98 (3.26 - 4.76) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.05 (3.32 - 4.85) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.12 (3.37 - 4.97) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.15 (3.39 - 5.01) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.17 (3.41 - 5) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.18 (3.43 - 5) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.2 (3.44 - 4.99) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.21 (3.42 - 4.99) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.21 (3.40 - 5) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.2 (3.40 - 4.96) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.19 (3.39 - 4.95) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.16 (3.36 - 4.92) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.14 (3.28 - 4.89) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.11 (3.22 - 4.93) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.27 (2.65 - 3.86) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.65 (0.05 - 8.94) | 2015 | Modelled | WHO |
| 0.14 (0.10 - 0.19) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.18 (0.13 - 0.25) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.18 (0.13 - 0.24) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.19 (0.14 - 0.25) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.2 (0.15 - 0.26) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.22 (0.16 - 0.30) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.25 (0.18 - 0.33) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.28 (0.20 - 0.38) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.32 (0.23 - 0.43) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.35 (0.25 - 0.46) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.36 (0.26 - 0.48) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.36 (0.26 - 0.48) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.36 (0.26 - 0.48) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.36 (0.26 - 0.48) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.36 (0.26 - 0.48) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.36 (0.26 - 0.48) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.57 (0.41 - 0.77) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.07 (0.76 - 1.44) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.66 (1.18 - 2.26) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.16 (1.53 - 2.98) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.39 (1.69 - 3.34) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.42 (1.73 - 3.30) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.44 (1.75 - 3.29) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.45 (1.76 - 3.29) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.46 (1.77 - 3.31) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.46 (1.76 - 3.30) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.45 (1.76 - 3.27) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.44 (1.76 - 3.21) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.42 (1.74 - 3.18) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.4 (1.71 - 3.18) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.37 (1.67 - 3.17) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.42 (0.09 - 2.08) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 207,365 (169,127 - 245,152) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 214,628 (174,244 - 252,342) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 212,151 (174,146 - 252,373) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 211,696 (174,348 - 253,437) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 215,159 (177,559 - 257,306) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 216,547 (176,039 - 257,820) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 215,382 (175,039 - 256,134) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 217,474 (177,004 - 258,867) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 220,510 (178,582 - 262,977) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 222,203 (179,846 - 265,460) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 220,298 (177,231 - 263,467) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 216,747 (175,884 - 256,662) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 214,499 (175,884 - 252,385) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 212,798 (174,364 - 251,212) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 210,850 (171,768 - 249,325) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 207,743 (167,581 - 247,202) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 205,093 (166,499 - 244,828) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 204,317 (166,796 - 245,211) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 204,194 (167,277 - 244,372) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 203,569 (166,803 - 245,102) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 201,280 (164,493 - 242,611) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 197,944 (162,518 - 238,462) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 194,746 (159,720 - 232,697) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 191,414 (156,651 - 226,976) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 187,726 (152,218 - 222,109) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 183,454 (147,563 - 217,723) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 178,704 (145,381 - 211,294) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 173,725 (140,602 - 204,671) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 168,515 (136,403 - 198,802) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 163,076 (129,353 - 193,702) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 157,470 (123,247 - 189,404) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 1.71 (1.14 - 2.45) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1.81 (1.36 - 2.33) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.77 (1.30 - 2.31) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.44 - 2.46) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.85 (1.36 - 2.43) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.88 (1.36 - 2.46) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.48 - 2.43) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.94 (1.49 - 2.47) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.44 - 2.45) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.96 (1.48 - 2.53) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.99 (1.50 - 2.56) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.97 (1.47 - 2.53) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.9 (1.42 - 2.48) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.43 - 2.48) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.46 - 2.49) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.97 (1.51 - 2.57) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.06 (1.55 - 2.65) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.99 (1.52 - 2.55) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.18 (1.63 - 2.87) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.1 (1.60 - 2.72) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.31 (1.74 - 3.02) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.36 (1.77 - 3.10) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.27 (1.69 - 3) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.08 (1.56 - 2.76) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.88 (1.39 - 2.53) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.67 (1.23 - 2.25) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.62 (1.18 - 2.21) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.68 (1.22 - 2.29) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.69 (1.19 - 2.35) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.69 (1.16 - 2.39) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.71 (1.14 - 2.45) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 347 | 2016 | Modelled | WHO |
| 73 (55 - 94) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 74 (54 - 96) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 86 (65 - 111) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 79 (58 - 104) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 82 (60 - 108) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 89 (68 - 112) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 92 (70 - 117) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 93 (69 - 118) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (73 - 124) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 100 (75 - 128) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 101 (75 - 130) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 101 (76 - 132) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 101 (75 - 130) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 104 (79 - 135) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 109 (83 - 142) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (85 - 143) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 122 (93 - 158) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 117 (89 - 151) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 129 (96 - 169) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 138 (104 - 181) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 144 (108 - 189) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 141 (105 - 186) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 131 (98 - 173) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 120 (88 - 162) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (82 - 152) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106 (77 - 145) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 108 (79 - 146) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 114 (80 - 159) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 116 (80 - 164) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (79 - 170) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (79 - 170) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 86 | 2019 | Survey/reported | WHO/UNICEF |
| 79 | 2020 | Survey/reported | WHO/UNICEF |
| 70 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Year of birth dose introduction
2017
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.98 (1.60 - 2.49) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.96 (1.58 - 2.46) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.95 (1.56 - 2.44) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.56 - 2.40) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.55 - 2.37) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.9 (1.53 - 2.36) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.89 (1.52 - 2.34) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.87 (1.51 - 2.33) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.86 (1.50 - 2.32) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.84 (1.48 - 2.31) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.47 - 2.28) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.44 - 2.25) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.77 (1.41 - 2.21) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.40 - 2.17) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.72 (1.38 - 2.15) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.72 (1.38 - 2.15) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.72 (1.38 - 2.15) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.72 (1.39 - 2.15) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.73 (1.39 - 2.16) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.73 (1.39 - 2.17) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.73 (1.39 - 2.17) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.73 (1.40 - 2.18) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.40 - 2.18) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.40 - 2.20) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.75 (1.40 - 2.21) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.75 (1.40 - 2.20) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.75 (1.41 - 2.20) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.75 (1.40 - 2.19) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.75 (1.41 - 2.19) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.76 (1.40 - 2.21) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.87 (1.50 - 2.34) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.2 (0.14 - 0.21) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 9.8 (7.70 - 11.90) | 2006 | Survey/reported | UNAIDS, PAHO, UNCIEF, 2009 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 67,341 (53,697 - 84,658) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 69,115 (55,406 - 86,282) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 70,873 (56,852 - 88,696) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 72,602 (58,294 - 91,376) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 74,309 (59,873 - 93,384) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 76,006 (60,942 - 96,008) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 77,656 (62,494 - 97,996) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 79,215 (63,654 - 99,715) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 80,741 (64,849 - 101,348) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 82,259 (66,310 - 103,221) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 83,820 (67,423 - 105,154) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 85,353 (68,820 - 106,993) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 86,782 (69,712 - 108,907) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 88,233 (71,335 - 110,717) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 89,818 (72,352 - 112,419) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 91,700 (73,555 - 114,338) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 94,167 (75,764 - 117,855) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 97,170 (78,011 - 121,968) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 100,439 (80,783 - 125,908) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 103,634 (83,545 - 129,914) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106,407 (85,500 - 133,241) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 108,897 (87,601 - 136,518) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 111,431 (89,916 - 138,535) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 113,993 (92,365 - 141,030) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 116,568 (94,106 - 144,479) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 119,149 (96,082 - 147,012) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 121,781 (98,427 - 151,260) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 124,404 (100,003 - 155,759) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 127,196 (102,448 - 159,436) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 130,269 (104,762 - 163,146) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 129,535 (104,091 - 162,282) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 3,700 (2,600 - 3,900) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 2.87 (1.98 - 4.03) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1.87 (1.46 - 2.36) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.38 - 2.33) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.9 (1.42 - 2.44) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.96 (1.53 - 2.45) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.46 - 2.49) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.95 (1.55 - 2.46) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.53 - 2.40) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.88 (1.49 - 2.36) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.88 (1.50 - 2.38) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.89 (1.49 - 2.39) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.86 (1.48 - 2.33) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.81 (1.43 - 2.27) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.45 - 2.32) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.84 (1.44 - 2.31) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.9 (1.49 - 2.42) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.51 - 2.44) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.09 (1.66 - 2.67) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.99 (1.57 - 2.53) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.02 (1.59 - 2.55) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.27 (1.79 - 2.92) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.2 (1.74 - 2.83) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.3 (1.80 - 2.97) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.37 (1.87 - 3.02) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.5 (1.94 - 3.21) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.68 (2.08 - 3.52) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.57 (2 - 3.31) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.81 (2.14 - 3.72) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.83 (2.07 - 3.82) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.85 (2.03 - 3.96) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.87 (1.98 - 4.03) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 199 | 2016 | Modelled | WHO |
| 199 (137 - 279) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 199 (137 - 279) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 195 (139 - 271) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 191 (140 - 258) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 187 (142 - 248) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 176 (137 - 232) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 167 (129 - 215) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 160 (124 - 205) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 149 (117 - 190) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 143 (111 - 184) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 138 (109 - 178) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 132 (105 - 170) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 124 (98 - 158) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 117 (93 - 148) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 114 (90 - 144) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 108 (85 - 137) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 105 (82 - 133) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 100 (78 - 125) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (76 - 121) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (75 - 121) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (76 - 119) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 95 (75 - 120) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 93 (74 - 117) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 91 (72 - 114) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 91 (72 - 113) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 90 (71 - 113) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 88 (69 - 110) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 85 (64 - 109) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 81 (61 - 104) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 76 (57 - 97) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 76 (59 - 96) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Year of birth dose introduction
2017
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)
Overview
HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
118
2019
(79 - 170)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
199
2019
(137 - 279)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.42
(%)
2020, latest modelled
(0.09 - 2.08(%))
WHO
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines